FDA Approves Takeda’s ORZEYFUL, the First Orexin Therapy for Adults with Narcolepsy Type 1

The U.S. Food and Drug Administration (FDA) has approved ORZEYFUL™ (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adults, marking the first approval of an oral orexin receptor 2 (OX2R) agonist and the first therapy that directly addresses the underlying orexin deficiency responsible for the disease. Developed by Takeda, the twice-daily oral treatment demonstrated clinically meaningful improvements across the full spectrum of NT1 symptoms in pivotal Phase 3 studies, representing a major shift from existing therapies that primarily manage individual symptoms.

First Orexin Replacement Therapy Targets the Cause of NT1

Narcolepsy type 1 is a rare, lifelong neurological sleep disorder caused by the loss of orexin-producing neurons in the brain. The resulting orexin deficiency disrupts the regulation of wakefulness, rapid eye movement (REM) sleep, and muscle tone, leading to excessive daytime sleepiness, cataplexy, fragmented nighttime sleep, sleep paralysis, and hypnagogic hallucinations.

Unlike conventional stimulants or medications that treat specific manifestations of the disease, oveporexton selectively activates the orexin receptor 2, restoring orexin signaling to address the underlying pathophysiology. The FDA approved the therapy as the first medicine indicated to treat narcolepsy type 1 as a complete disorder rather than targeting isolated symptoms.

The condition affects an estimated 120,000 people in the United States, with symptoms often impairing education, employment, daily functioning, and quality of life.

Phase 3 Program Demonstrated Broad Clinical Benefit

The approval is supported by the global Phase 3 FirstLight (TAK-861-3001, NCT06470828) and RadiantLight (TAK-861-3002, NCT06505031) trials, together with the broader clinical development program.

The randomized, double-blind, placebo-controlled 12-week studies enrolled 273 adults with narcolepsy type 1. Patients receiving oveporexton 2 mg twice daily experienced statistically significant improvements compared with placebo across multiple clinically important outcomes.

The therapy improved excessive daytime sleepiness, reduced the frequency of cataplexy attacks, and enhanced health-related quality of life. Participants also reported meaningful improvements in sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep, reflecting benefits across the complete symptom profile of NT1 rather than isolated endpoints.

Oveporexton was generally well tolerated throughout the clinical program. The most frequently reported adverse events included insomnia, urinary urgency, increased urinary frequency, and excessive salivation. Treatment discontinuation due to adverse events was uncommon.

The prescribing information advises against concomitant use with strong CYP3A inhibitors, and the safety and efficacy of the medicine have not been established in individuals younger than 18 years.

Experts Highlight a Shift in Narcolepsy Treatment

Julie Kim, President and Chief Executive Officer of Takeda, said the approval introduces an entirely new therapeutic class that could redefine treatment for people living with narcolepsy type 1 by addressing the disease itself rather than individual symptoms.

Dr. Emmanuel Mignot, principal U.S. investigator in the Phase 3 program, noted that the availability of the first approved orexin therapy changes the clinical discussion around treatment by offering a disease-targeted approach.

FDA officials also emphasized the significance of the approval. Tiffany R. Farchione, M.D., Director of the Division of Psychiatry within the FDA’s Center for Drug Evaluation and Research, said the medicine is the first to restore the missing orexin signaling that drives the disorder, treating narcolepsy type 1 as a unified disease instead of addressing symptoms individually.

Commercial Launch Expected Following DEA Scheduling

ORZEYFUL received both Breakthrough Therapy Designation and Priority Review during development, reflecting its potential to offer substantial improvement over available therapies.

Before commercial distribution can begin in the United States, the Drug Enforcement Administration (DEA) must complete scheduling under the Controlled Substances Act, a process expected within approximately 90 days of FDA approval. Following scheduling, Takeda plans to launch ORZEYFUL through a specialty pharmacy network for eligible adults with narcolepsy type 1.

The company is also investigating orexin receptor agonists across additional neurological disorders, positioning the approval as the first milestone in a broader therapeutic strategy centered on restoring orexin signaling.

Reference

FDA Approves ORZEYFUL for Adults with Narcolepsy Type 1

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms | FDA